Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05683912
NCT05683912
Completed
Not Applicable

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece: The ADMIRE Study

University of Athens1 site in 1 country100 target enrollmentSeptember 1, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetic Macular Edema
DrugsAflibercept

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetic Macular Edema
Sponsor
University of Athens
Enrollment
100
Locations
1
Primary Endpoint
Change in best-corrected visual acuity
Status
Completed
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Registry
clinicaltrials.gov
Start Date
September 1, 2019
End Date
December 15, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University of Athens
Responsible Party
Principal Investigator
Principal Investigator

Irini Chatziralli

Assistant Professor in Ophthalmology

University of Athens

Eligibility Criteria

Inclusion Criteria

  • •Patients with DM, able to give written informed consent Patients with DME\>320 μm, who need treatment

Exclusion Criteria

  • •Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Outcomes

Primary Outcomes

Change in best-corrected visual acuity

Time Frame: 12 months

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or RanibizumabDiabetic Macular Edema
NCT02000102Stanford University14
Unknown
Phase 4
Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)Macular Edema, Diabetic
NCT02788877Pusan National University Hospital48
Completed
Phase 4
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or BevacizumabDiabetic RetinopathyMacular Edema
NCT02559180Rishi Singh20
Completed
Phase 4
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular EdemaRetinal Diseases
NCT02646670Instituto de Olhos de Goiania20
Completed
Phase 4
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)Diabetic Macular Edema
NCT04087746Minia University400